Aurobindo Pharma Limited (AUROPHARMA.BO)
| Previous close | 874.50 |
| Open | 871.00 |
| Bid | 861.00 x 0 |
| Ask | 862.00 x 0 |
| Day's range | 856.20 - 873.90 |
| 52-week range | 281.15 - 1,023.10 |
| Volume | 61,657 |
| Avg. volume | 157,875 |
| Market cap | 505.494B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 16.98 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 762.03 |
- Business Wire
New Mountain Completes Acquisition of Natrol
An affiliate of New Mountain Capital, LLC ("New Mountain") announced the completion of its acquisition of Natrol, a leading vitamins, minerals and supplements brand, focused on sleep, mood & stress and brain health. New Mountain intends to combine Natrol with Jarrow Formulas ("Jarrow"), another New Mountain portfolio company.
- Business Wire
New Mountain Capital to Acquire Natrol from Aurobindo Pharma
New Mountain Capital announced that it has reached a definitive agreement with Aurobindo Pharma to acquire Natrol and combine it with Jarrow Formulas, another New Mountain Capital portfolio company. The transaction is expected to close by January 2021 subject to customary closing conditions and regulatory approvals.
- Stockopedia
Brokers bullish on Aurobindo Pharma shares
The Aurobindo Pharma (NSI:AUROPHARMA) share price has risen by 12.7% over the past month and it’s currently trading at 865.75. For investors considering whethe...
